Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...

Regeneron stock XX on XX after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD.

On Friday, the FDA approved Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD: Paris Monday, September 30, 2024, 11:00 Hrs [IST] The Nat ...

Regeneron (REGN) and Sanofi's (SNY) asthma therapy Dupixent receives FDA approval for label expansion in treating certain ...

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing ...

The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary ...

Regeneron's R&D expenses are projected to reach $5 billion, but the business remains highly profitable. Read why I rate REGN ...

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the National Medical Products Administration in China has ...

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) ...